Description: Biosergen AS is a biotech company developing new drugs based on cutting edge biosynthetic engineering of natural products, combined with chemical synthesis. Established in 2004, the company is based in Trondheim, Norway and focuses its innovative research on fighting systemic fungal infections. Biosergen’s lead compound, BSG005, is currently in pre-clinical development phase.
The company is currently focusing on delivering a proof-of-concept program for BSG005 as well as on seeking partners for out-licensing and the continued development of BSG005.
The current major owners of Biosergen are Karolinska Development AB, Rosetta Capital, Östersjöstiftelsen, and Sintef Venture II.